To assess plasma phosphorylated tau181 (p‐tau181) levels in Alzheimer's disease (AD), cognitively impaired non‐AD participants (CI non‐AD) and Control participants in the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset that could… Click to show full abstract
To assess plasma phosphorylated tau181 (p‐tau181) levels in Alzheimer's disease (AD), cognitively impaired non‐AD participants (CI non‐AD) and Control participants in the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset that could potentially act as reference data for clinic diagnoses of AD.
               
Click one of the above tabs to view related content.